Genesin Genetics, Genzine Genetics

Gensim was once the third or fourth largest diagnostic reference flap in the us. The diagnostics division became a key part of genzine's strategy to develop targeted therapies for cancer drug development an big farma companies. Gensim is now worth more than $20 billion, and has become one of the world's most successful private equity firms.